ClinicalTrials.gg
RecruitingNCT07025018Updated Aug 1, 2025

Phase I Study of HMPL-306 for the Treatment of Gliomas With IDH1 and/or IDH2 Mutations

A Phase 1 interventional study of HMPL-306 in Gliomas Harboring IDH1 and/or IDH2 Mutations, sponsored by Hutchmed. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-01.

Sponsored by Hutchmed · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 162 studies in Glioma with a site in China — 70 open to participants now, 82 under way, 3 of them phase 3. Glioma · China.

Planned enrollment
41st of 112
52 · median 40
Started
2025
with 15 others
Phase 1
36 of 162
18 open now
Primary completion
2026-12
later than 33 of 81 live
Registered
135th of 162
by date

Among the 162 studies in Glioma with a site in China, this one is the 41st largest by planned enrollment of the 112 interventional ones that give a count, is one of 16 that started in 2025, is one of 36 in phase 1, reaches primary completion later than 33 of the 81 other live ones, and was the 135th registered.

Glioma

1,453 studies on the registry are indexed under Glioma; 349 are open to participants now.

Browse Glioma studies →

Open to participants now

70 of the 162 studies in Glioma with a site in China are open now. Recruiting first, the newest first:

64 more — sign in →

All 70 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 267 Glioma studies recruiting now, 165 (62%) set no upper age limit and 56 (21%) stop at 75 or younger; 62 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 162 studies in Glioma with a site in China, or all of them as a file.
02

Study summary

This study is a multicenter, randomized controlled Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations

Read the detailed description

HMPL-306 is a dual IDH1/2 inhibitor. This is a multicenter, randomized controlled phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations.

The study consists of 2 parts: Part 1 (safety lead-in phase) and Part 2 (perioperative phase). Part 1 will determine safety and DLT. Part 2 will administer the HMPL-306 or no treatment to mIDH-positive gliomas.

03

Conditions studied

  • Gliomas Harboring IDH1 and/or IDH2 Mutations

Browse trials for

Keywords

  • gliomas
  • randomized controlled
  • Multicenter
  • IDH1 mutations
  • IDH2 mutations
  • safety run-in
  • MRI/MRS examination
  • Phase I
  • clinical study
  • pharmacokinetics (PK)
  • pharmacodynamics (PD)
  • efficacy
  • HMPL-306
  • perioperative study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully informed about the study and voluntarily sign the form (ICF).
  2. Age ≥ 18 years.
  3. Safety Lead-In Phase: Patients with gliomas of a documented IDH1 and/or IDH2 mutation. Perioperative Study Phase: Patients with gliomas of definitive or suspected IDH1 and/or IDH2 mutations scheduled for surgery.
  4. All patients must have at least one .
  5. Performance Status (KPS) score ≥ 80% .
  6. In the investigator's judgment, a of ≥ 12 weeks.
  7. Sufficient bone marrow and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with IDH inhibitors.
  2. Unresolved toxicity from previous antitumor treatments not reverted to ≤ Grade 1 (except for alopecia, skin pigmentation changes, and ≤ Grade 2 peripheral neuropathy).
  3. Patients assessed by researchers to have high-risk or unstable conditions.
  4. Having other or a history of other malignancies within 5 years prior to screening.
  5. History of liver disease, including active infection with viral hepatitis, or other active hepatitis, alcoholic liver disease, cirrhosis, etc.
  6. Patients with infection.
  7. Pregnancy (positive pregnancy test before dosing) or currently breastfeeding women.
  8. Presence of diseases or conditions affecting drug absorption.
  9. Any other conditions, in the investigator's judgment, unsuitable for the study drug, will result in exclusion.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Experimental
    Safety run-in

    This phase plans to enroll patients with gliomas of IDH1 and/or IDH2 mutations. The DLT will be evaluated during the first 28 days after the initial dosage.

    Drug: HMPL-306

  • Experimental
    Perioperative study phase

    This phase plans to enroll patients with gliomas of definitive or suspected IDH1 and/or IDH2 mutations, who are scheduled for surgery. Patients who meet the inclusion criteria will be randomized to groups A, B, or C, to receive or not receive HMPL-306 treatment before surgery.

    Drug: HMPL-306

Interventions

  • IDH small molecule inhibitor

06

What researchers measure

Primary outcomes

  1. Number of Subjects with Dose Limiting Toxicities (DLTs)

    DLT is defined as an adverse event (AE) that meets protocol defined DLT criteria during cycle 1 and is at least possibly related to study drug.

    Time frame: Up to 28 days after first dose of study drug

  2. RP2D

    Determine the Phase II recommended dose (RP2D) of HMPL-306 in patients with gliomas harboring IDH1 and/or IDH2 mutations based on a comprehensive assessment.

    Time frame: From first dose of study drug to the time of progressive disease, assessed up to 24 months on average

Secondary outcomes

  1. Maximum serum drug concentration

    Blood samples will be obtained from all patients for determination of the maximum serum concentration of HMPL-306.

    Time frame: PK/PD weeks at screening through safety follow-up, assessed up to 24 months on average

  2. Time to maximum concentration

    Blood samples will be obtained from all patients for determination time to maximum concentration of HMPL-306.

    Time frame: PK/PD weeks at screening through safety follow-up, assessed up to 24 months on average

  3. Area under the concentration-time curve (AUC)

    Blood samples will be obtained from all patients for determination of the AUC of HMPL-306

    Time frame: PK/PD weeks at screening through safety follow-up, assessed up to 24 months on average

  4. Concentration of 2-HG in brain tumor tissue

    Brain tumor tissue will be obtained from suitable patients for determination concentration of 2-HG.

    Time frame: PK/PD weeks at screening through safety follow-up, assessed up to 24 months on average

Other outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the proportion of subjects with confirmed best overall tumor response of Complete Response (CR) or Partial Response (PR) or Minor Response (MR).

    Time frame: From first dose of study drug to the time of progressive disease, assessed up to 24 months on average

  2. Duration of response (DoR)

    DoR defined as the time from the date of the first CR or PR or MR to the first date of progressive disease (PD) or death from any cause.

    Time frame: From first dose of study drug to the time of disease relapse or death, whichever comes first, assessed up to 24 months on average

  3. Progression-free Survival (PFS)

    PFS is defined as time from first dose date of study drug to date of progression or date of death from any cause, whichever occurred first.

    Time frame: From first dose of study drug to the time of progressive disease or death due to any causes, whichever comes first, assessed up to 24 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 47 industry-sponsored phase 1 interventional studies under Glioma, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 121. This study's planned 17 months is below that.

Counting every sponsor, half of 213 studies reached it within 59 months; a quarter within 36 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 17, 2025
StartActual
Jul 15, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Aug 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07025018
Lead sponsor
Hutchmed
Responsible party
Sponsor
First posted
Jun 17, 2025
Start date
Jul 15, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Aug 1, 2025

Study contacts

Tinghua Song
Contact
tinghuas@hutch-med.com
+86 21 2067 1822
Jinsong Wu
principal investigator · Huashan Hospital
Bo Zhang
study director · Hutchmed

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranosidenib

Start the discussion